文献速递免疫规划卫生政策与健康促进

流行性传染病疫苗研发成本估算:成本最小化研究

Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study.
PubMed 文献 · Lancet Glob Health · 2018-10-18

该研究从临床前至2a期收集了11种优先流行性传染病的224个疫苗候选株,采用线性回归与随机优化模型估算研发成本。

核心结论

  • 该分析为11种流行性传染病的疫苗研发管线及相关成本提供了新证据,突显了实现疫苗研发准备目标的资金需求与研发缺口。

研究设计与样本

  • 从临床前至2期收集了11种优先流行性传染病的224个疫苗候选株,采用线性回归模型识别成本驱动因素,并基于已发表的研发成功概率模拟成本,通过随机优化模型确定最低成本。

主要发现

  • 既往许可经验和间接成本是研发成本的上行驱动因素。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Coalition for Epidemic Preparedness Innovations was established in 2016, to develop vaccines that can contribute to preparedness for outbreaks of epidemic infectious diseases. Evidence on vaccine development costs for such diseases is scarce. Our goal was to estimate the minimum cost for achieving vaccine research and development preparedness targets in a portfolio of 11 epidemic infectious diseases, accounting for vaccine pipeline constraints and uncertainty in research and development preparedness outcomes. METHODS: We assembled a pipeline of 224 vaccine candidates from preclinical through to phase 2 for 11 priority epidemic infectious diseases. We used a linear regression model to identify drivers of development costs from preclinical through to end of phase 2a. Drawing from published estimates of vaccine research and development probabilities of success, we simulated costs for advancing these 224 vaccine candidates through to the end of phase 2a. We combined these findings to determine minimum costs for progressing at least one vaccine through to the end of phase 2a per epidemic infectious disease by means of a stochastic optimisation model. FINDINGS: The cost of developing a single epidemic infectious disease vaccine from preclinical trials through to end of phase 2a is US$31-68 million (US$14-159 million range), assuming no risk of failure. We found that previous licensure experience and indirect costs are upward drivers of research and development costs. Accounting for probability of success, the average cost of successfully advancing at least one epidemic infectious disease vaccine through to the end of phase 2a can vary from US$84-112 million ($23 million-$295 million range) starting from phase 2 to $319-469 million ($137 million-$1·1 billion range) starting from preclinical. This cost includes the cumulative cost of failed vaccine candidates through the research and development process. Assuming these candidates and funding were made available, progressing at least one vaccine through to the end of phase 2a for each of the 11 epidemic infectious diseases would cost a minimum of $2·8-3·7 billion ($1·2 billion-$8·4 billion range). INTERPRETATION: Our analysis provides new evidence on vaccine research and development pipelines and associated costs for 11 epidemic infectious diseases, highlighting both funding needs and research and development gaps for achieving vaccine research and development preparedness targets. FUNDING: This work was partly supported by the Research Council of Norway through the Global Health and Vaccination Programme GLOBVAC.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Gouglas D, Thanh Le T, Henderson K, et al. Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. Lancet Glob Health. 2018. PMID: 30342925. doi:10.1016/S2214-109X(18)30346-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。